Exclusive License For Australian Biotech

4 November 1996

Australian company AMRAD has signed an exclusive worldwide license agreement with the Australian National University for its research on an improved form of the AMRAD protein expression system Glutathione S-transferase (GST) Gene Fusion System. The agreement covers technology developed by Graeme Cox and his group at the John Curtin School of Medical Research, and commercialized by ANUTECH, the University's commercial subsidiary.

A spokesman for ANUTECH explained that "a protein expression system is a recombinant method designed to produce large quantities of a particular protein. However, in many cases the protein is expressed as 'inclusion bodies' - insoluble globules of protein which, while they may be useful as a purification process, also mean that it can be very difficult to retrieve the protein in an active form."

He said Prof Cox' group has been investigating the production of different membrane proteins for characterization purposes but initial experiments produced inclusion bodies rather than active proteins. The team was able to successfully produce active forms of the proteins of interest by adapting the GST Gene Fusion System, he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight